November 2, 2023
November 2, 2023 —
Psychedelic researchers are exploring psychedelics at all levels, from the cellular to the clinical, and in a range of fields and departments, from neuroscience and pain medicine to psychology and psychiatry.
June 10, 2024
June 10, 2024 —
Americans’ interest in the potentially harmful “magic mushroom” Amanita muscaria is soaring, according to a new study. UC San Diego researchers suggest the market growth may be driven by clinical research on psilocybin’s safety and efficacy in treating depression.
May 21, 2020
May 21, 2020 —
…species’ active ingredients are psilocybin and psilobin. iStock.com/horkins The Psychedelic Science of Pain Psychedelics and Health Research Initiative explores new territory in treating pain In the last few years, new research has demonstrated the powerful potential for classical psychedelics, especially psilocybin (the active compound in “magic mushrooms”), to treat a…
February 17, 2021
February 17, 2021 —
The Psychedelics and Health Research Initiative at UC San Diego has received a $1.3 million grant from the Steven & Alexandra Cohen Foundation to fund a clinical trial investigating the therapeutic potential of psilocybin in treating phantom limb pain.
November 2, 2023
November 2, 2023 —
Psychedelic research has taken place at UC San Diego since the 1970s. But today, thanks to an interdisciplinary team from departments all across campus, that research has expanded to include human clinical trials exploring a range of treatments including chronic pain and mental health.
June 28, 2024
June 28, 2024 —
Loosening local, state and federal regulations on cannabis and psychedelics has increased Americans’ interest in microdosing, according to a study from researchers at the University of California San Diego. Published in JAMA Health Forum, the study found that the rate of microdosing-related Google searches grew by 1250% from 2015 to…
November 5, 2019
November 5, 2019 —
Limitless: The Qualcomm Institute’s Albert Lin has launched a new project to help the world’s 40 mission amputees who live without access to a prosthesis.
December 18, 2020
December 18, 2020 —
…species’ active ingredients are psilocybin and psilobin. iStock.com/horkins There’s potential for psychedelics to address chronic pain conditions. Preliminary findings from a review paper showed that psychedelics can produce significant, meaningful and lasting reductions of chronic pain conditions such as cluster headache, phantom-limb pain and others. This study also offers insight…